Avoro Capital Advisors LLC Takes $32.77 Million Position in Lexeo Therapeutics, Inc. $LXEO

Avoro Capital Advisors LLC acquired a new position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,300,000 shares of the company’s stock, valued at approximately $32,769,000. Lexeo Therapeutics makes up about 0.3% of Avoro Capital Advisors LLC’s holdings, making the stock its 29th largest holding. Avoro Capital Advisors LLC owned about 4.52% of Lexeo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Graham Capital Management L.P. bought a new position in Lexeo Therapeutics in the fourth quarter worth approximately $327,000. Persistent Asset Partners Ltd bought a new position in Lexeo Therapeutics in the fourth quarter worth approximately $159,000. OMERS ADMINISTRATION Corp bought a new position in Lexeo Therapeutics in the fourth quarter worth approximately $208,000. Squarepoint Ops LLC bought a new position in Lexeo Therapeutics in the fourth quarter worth approximately $920,000. Finally, Spruce Street Capital LP bought a new position in Lexeo Therapeutics in the fourth quarter worth approximately $1,738,000. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

LXEO has been the subject of a number of recent research reports. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.14.

Lexeo Therapeutics Trading Up 2.2%

NASDAQ LXEO opened at $4.75 on Wednesday. The firm’s fifty day simple moving average is $5.48 and its two-hundred day simple moving average is $6.98. Lexeo Therapeutics, Inc. has a 12-month low of $3.60 and a 12-month high of $10.99. The firm has a market capitalization of $372.97 million, a P/E ratio of -3.28 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. As a group, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,644 shares of company stock valued at $336,462 over the last 90 days. 2.00% of the stock is currently owned by insiders.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.